Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences Chairman & CEO Daniel O'Day reported open-market sales of 15,000 shares of Common Stock. The trades took place on June 1, 2026 in three transactions at prices around $131 per share. Footnotes state these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026, indicating the timing was scheduled in advance rather than discretionary.
GILD — Rule 144 notice for proposed resale of restricted shares. The filing lists 35,000 shares of Common stock associated with Morgan Stanley Smith Barney LLC as broker/dealer. The record shows prior dispositions of 10,000 shares on 03/27/2026 and 10,000 shares on 04/28/2026 with the reported proceeds for each transaction.
Gilead Sciences, Inc. entered into an Eleventh Supplemental Indenture to support a new multi-tranche senior notes offering under its existing base indenture. The company issued 4.250% Senior Notes due 2028 with an aggregate principal amount of $500,000,000 and 4.400% Senior Notes due 2029 with an aggregate principal amount of $1,000,000,000.
It also issued 4.600% Senior Notes due 2031 with an aggregate principal amount of $1,000,000,000 and 4.900% Senior Notes due 2034 with an aggregate principal amount of $500,000,000. These notes were sold in a public offering from an effective Form S-3 shelf, with semi-annual interest payments until their respective maturities. Gilead plans to use the net proceeds for general corporate purposes, including potential acquisitions, investments, strategic transactions or other business opportunities.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at an average price of $132.27 per share. After this transaction, he directly holds 173,191 shares of Gilead common stock. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating the trade was scheduled in advance rather than timed discretionarily.
Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier reported option exercises and share sales. On May 15, 2026, she exercised 25,000 non-qualified stock options at an exercise price of $66.64 per share and acquired the same number of common shares.
That day she also completed open-market sales totaling 28,000 shares of Gilead common stock in multiple trades at prices ranging from about $129.66 to $132.78 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, she directly holds 125,779 common shares and retains 23,110 stock options with a $66.64 exercise price expiring on July 24, 2029.
Gilead Sciences, Inc. is conducting a primary offering of senior unsecured notes totaling $3.0 billion across four series: $500 million 4.250% due 2028, $1.0 billion 4.400% due 2029, $1.0 billion 4.600% due 2031 and $500 million 4.900% due 2034. Interest accrues from May 20, 2026 and is payable semiannually on May 20 and November 20, beginning November 20, 2026. Net proceeds are estimated at approximately $2.99 billion and will be used for general corporate purposes, potentially including acquisitions, investments and other strategic uses. The notes are senior unsecured obligations, rank pari passu with other senior unsecured debt and will not be listed on any exchange.
GILD filed a Form 144 reporting proposed sales of specified common stock. The notice lists a Stock Option Exercise of 25,000 shares dated 05/15/2026, 494 restricted shares dated 12/10/2024, and 2,506 performance shares dated 02/04/2025.
The filing also records sales by Johanna Mercier in the prior three months: 3,000 shares on 04/15/2026 ($422,880.00), 3,000 shares on 03/16/2026 ($432,690.00), and 28,000 shares on 02/17/2026 ($4,324,227.70).
Andrew Dickinson submitted a Form 144 notice indicating a proposed sale of 3,000 shares of Common Stock described as Performance Shares (issued 01/24/2023) through Morgan Stanley Smith Barney LLC. The filing also lists three recent sales of 3,000 shares each on 02/17/2026, 03/16/2026, and 04/15/2026 with reported proceeds.
Gilead Sciences, Inc. is offering multiple series of senior unsecured notes under a preliminary prospectus supplement related to an effective shelf registration. The notes will be senior unsecured obligations that rank equally with Gilead’s other senior unsecured debt, will be issued in book-entry form through DTC and are payable semiannually commencing in 2026.
The indenture permits optional redemption (including at Par Call Dates) and requires an offer to repurchase the notes at 101% of principal upon a Change of Control Triggering Event. Net proceeds are designated for general corporate purposes. The prospectus supplement incorporates certain SEC filings by reference, including the Form 10-K for the year ended and Form 10-Q for the quarter ended .
GILEAD SCIENCES, INC. filed a Form 13F reporting its institutional investment manager holdings. The report lists 6 information-table entries with a total reported market value of $2,117,784,504. The filing names Gilead Therapeutics A1 Unlimited Co as an other included manager and is signed by CFO Andrew D. Dickinson on 05-08-2026.